ENO2 and prostate carcinoma: Serum NSE concentrations are often increased in patients with other diseases, such as thyroid cancer, prostate carcinoma, neuroblastoma, and small cell lung carcinoma (SCLC) [8]; on the contrary, neuronal damage is associated with decreased levels of NSE [30].